Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial

SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to

Related Keywords

China ,Copenhagen ,Køavn ,Denmark ,United States ,Hong Kong ,Beijing ,Suzhou ,Jiangsu ,Thailand ,Taipei ,T Ai Pei ,Taiwan ,Shanghai ,Chinese ,Ascendis Pharma ,Yu Yongguo ,National Health Commission ,European Commission ,Drug Administration ,Transcon Technology ,National Health Commission On ,Clinical Genetics Center ,Shanghai Jiao Tong University School Of Medicine ,National Health ,Executive Director ,Xinhua Hospital ,Shanghai Jiao Tong University School ,Orphan Designation ,Orphan Drug Designation ,United States Food ,Thailand Business ,